Ask Warren

JONBUR Research · Update note

Curiox Biosystems · 445680 · Medical & precision devices

Curiox Biosystems: Shares Fall 15.3% in Five Days on Heavy Volume, No Filing Explains the Move

Why this report

Written after:

  • Big price moveShares down 15.3% over 5 trading days on 3.0× normal volumeOct 26, 2026

Curiox Biosystems shares fell 15.3% over five trading days to ₩58,700 on 3.0 times normal volume, partly reversing the prior week's rise. Nothing in the data explains the drop, and the business fundamentals are unchanged.

Written Oct 27, 2026 · Data as of Oct 26, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

What happened

Between 2026-10-20 and 2026-10-26 the share price fell 15.3% on volume about 3.0 times normal. The close on 2026-10-26 was ₩58,700, against ₩69,300 cited in the previous report. No filing excerpts accompany the move, and no smaller recent events are listed as background. The most recent filings are a trading plan report for executives and major shareholders (2026-10-02) and amended annual reports (2026-10-01); none is shown to explain the fall. Two news items from mid-October (Money Today) listed the stock among market picks, but they do not explain this drop.

Over 20 days, foreigners were net sellers of about ₩14.0B, institutions net buyers of about ₩4.0B and retail investors net buyers of about ₩9.7B. Foreign ownership is 5.0%, down from 9.6% sixty days ago. The short balance is 1.7%. The share price is still up 18.3% over one month and 46.9% over three months, but down 13.7% over one year.

What it changes for the thesis

The previous report described a small, loss-making company whose share price had run well ahead of its results, and noted that nothing in the data explained the 27.9% rise. This fall does not change that picture. It also lacks an identifiable cause, so it points to volatile trading rather than new information about the business.

The financials are unchanged: trailing twelve-month revenue is ₩5.7B, operating loss ₩13.0B, free cash flow negative ₩9.3B and cash ₩10.5B, with no borrowings. Liabilities are low at 8.9% of equity, which remains a modest support. Compared with the previous report, institutions' net buying has fallen from about ₩7.0B to ₩4.0B, while foreigners are still selling and retail investors are buying.

What it changes for the valuation

The model has no estimate for this company in this update. The previous report showed a base of ₩379 per share, a bear of ₩389 and a bull of ₩382, as a model estimate based on the assumptions shown. It also noted that the bear case sat above the base, so the scenario outputs were not well behaved with negative cash flows. Those figures should be treated with caution and not as a current estimate.

At ₩58,700 the market capitalisation is about ₩1,011B. Price-to-book is 20.6, down from 24.4 in the previous report, and price-to-sales is 176.3, down from 208.2. Peers show price-to-book of 3.0 to 15.6. Price-to-earnings and EV/EBITDA cannot be calculated because of losses. The valuation remains far above what the reported financials support, even after the fall.

Closing view

The 15.3% drop on heavy volume narrows the gap between the share price and the reported financials, but it adds no fundamental information. Two sharp moves in two weeks, up 27.9% and then down 15.3%, both without a filing to explain them, suggest price action driven by trading rather than disclosed developments. Losses, cash use and falling foreign ownership are unchanged. Without a filing on products, orders or funding, and without a current model estimate, the evidence does not show what price level the business supports.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Filings and data used

Report history

  1. Oct 27, 2026Update noteBig price moveCuriox Biosystems: Shares Fall 15.3% in Five Days on Heavy Volume, No Filing Explains the Move
  2. Oct 19, 2026Update noteBig price moveCuriox Biosystems: Shares Rise 27.9% in Five Days on Heavy Volume, No Filing Explains the Move
  3. Oct 18, 2026InitiationStart of coverage (300 largest)Curiox Biosystems: Sharp Share Price Rally Against Deep Losses and a Model Estimate Far Below the Market Price

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information